Inicio > Medicina Interna > La gota y sus comorbilidades. Amiga o enemiga > Página 6

La gota y sus comorbilidades. Amiga o enemiga

35. Choi HK, Ford E. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007; 120: 442–7.
36. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008; 93 (11 Suppl. 1): S9–30.
37. Bantle JP. Dietary fructose and metabolic syndrome and diabetes. J Nutr 2009; 139: 1263S–8S.
38. Choi JWJ, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008; 59: 109–16.
39. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology (Oxford) 2007; 46: 1441–4.
40. Halpern R, Fuldeore MJ, Mody RR, Patel PA. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009; 15: 3–7.
41. Kim KY, Schumacher HR. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003; 25: 1593–617.
42. Wu EQ, Patel PA. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm 2008; 14: 164–75.
43. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisationin US veterans. Ann Rheum Dis 2008; 67: 1310–6.
44. Kleinman NL, Brook RA. The impact of gout on work absence and productivity. Value Health 2007; 10: 231–7.
45. Cannon P, Stason W, Demartini F, Sommers S, Laragh J. Hyperuricaemia in primary and renal hypertension. N Engl J Med 1966;275:457–64.
46. Annemans L, Spaepen E, Gaskin M. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008;67:960–6.
47. Chen SY, Chen CL, Shen ML. Manifestations of metabolic syndrome associated with male gout in different age strata. Clin Rheumatol 2007;26:1453–7.
48. Johnson R, Kang DH, Feig D. Is there a pathogenic role for uric acid in hypertension and cardiovascular renal disease? Hypertension 2003;41:1183–90.
49. Burnier M, Rutschmann B, Nussberger J. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22:339–47.
50. Soffer B, Wright J, Pratt J. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112–7.
51. Chanard J, Toupance O, Lavaud S. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant 2003;18:2147–53.
52. Choi H, Soriano L, Zhang Y, Rodriguez L. Anti-hypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. Br Med J 2012;344-60.
53. Hueskes B, Roovers E, Mantel-Teeuwisse A. Use of diuretics and the risk of gouty arthritis: a systematic review. Semin Arthritis Rheum 2012;41:879–89.
54. Kanbay M, Ozkara A, Selcoki Y. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal function. Int Urol Nephrol 2007;39:1227–33.
55. Feig D, Soletsky B, Johnson R. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension. JAMA 2010;300:924–32.
56. Sanchez-Lozada L, Tapia E, Soto V. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 2008;23:1179–85.
57. Krishnan E, Baker J, Furst D, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688–96.
58. Krishnan E, Svendsen K, Neaton J. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168:1104–10.
59. Choi H, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894–900.
60. Edwards N. The role of hyperuricaemia in vascular disorders. Curr Opin Rheum 2009;21:132–7.
61. Kim S, Guevara J, Kim K. Hyperuricaemia and risk of stroke: a systematic review and meta-analysis. Arthritis Care Res 2009;61:885–92.
62. Baker J, Schumacher H, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology 2007;58:450–7.
63. Thansaaoulis G, Brophy J, Richard H, Pilote L. Gout, allopurinol use and heart failure outcomes. Arch Intern Med 2010;170:1358–64.
64. Hare J M, Mangal B, Brown J. Impact of oxypurinol in patients with symptomatic heart failure. J Am Coll Cardiol 2008;51:2301–9.
65. Norman A, Ang D, Ogston S, Lang C, Struthers A. Effect of high dose allopurinol on exercise in patients withy chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010;375:2161–7.
66. Rentoukas E, Tasarouhas K, Tsitsimpikou C. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol 2010;145:257–8.
67. Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Care Res 2002;47:610–3.
68. Mikuls T, Farrar J, Bilker W. Gout epidemiology: results from the UK general practice research database, 1990-1999. Ann Rheum Dis 2005;64:267–72.
69. Stamp L, Zhu X, Dalbeth N. Serum urate as a soluble biomarker in chronic gout—evidence that serum urate fulfils the OMERACT validation criteria for soluble biomarkers. Semin Arthritis Rheum 2011;40:483–500.
70. Fessel WJ, Barr GD. Uric acid, lean body weight, and creatinine interactions: results from regression analysis of 78 variables. Semin Arthritis Rheum 1977;7:115–21.
71. Woo J, Swaminathan R, Cockram C, Lau E, Chan A. Association between serum uric acid and some cardiovascular risk factors in a Chinese population. Postgrad Med J 1994;70:486–91.
72. Nakanishi N, Suzuki K, Kawashimo H, Nakamura K, Tatara K. Serum uric acid: correlation with biological, clinical and behavioural factors in Japanese men. J Epidemiol 1999;9:99–106.
73. Lin CS, Hung YJ, Chen GY. A multicenter study of the association of serum uric acid, serum creatinine and diuretic use in hypertensive patients. Int J Cardiol 2009;148:325–30.
74. Gresham GE, Keller MD. Hyperuricemia and chronic renal disease. J Chronic Dis 1971;23:755–62.
75. Sari I, Akar S, Pakoz B. Hyperuricemia and its related factors in an urban population, Izmir, Turkey. Rheumatol Int 2009;29:869–74.
76. Kono S, Shinchi K, Imanishi K, Honjo S, Todoroki I. Behavioural and biological correlates of serum uric acid: a study of self-defence officials in Japan. Int J Epidemiol 1994;23:517–22.
77. Tuomilehto J, Zimmet P, Wolf E. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol 1988;127:321–36.
78. Salazar M, Carbajal H, Marillet A. Glomerular filtration rate, cardiovascular risk factors and insulin resistance. Medicina (B Aires) 2009;69:541–6.
79. Borges R, Hirota A, Quinto B. Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy. J Clin Hypertens 2009;11:253–9.